A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01022346
First received: November 20, 2009
Last updated: August 11, 2016
Last verified: August 2016

November 20, 2009
August 11, 2016
August 2009
September 2013   (final data collection date for primary outcome measure)
Percentage of participants with CIN2/CIN3 associated with HPV16 single infection who achieved Histologic resolution (Defined as no CIN), determined by evaluation of tissue derived from surgical excision [ Time Frame: Month 6 ] [ Designated as safety issue: No ]
Histologic resolution [ Time Frame: at month 6 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01022346 on ClinicalTrials.gov Archive Site
  • Percentage of participants who achieved Histologic resolution (Defined as no CIN), determined by evaluation of tissue derived from surgical excision [ Time Frame: Months 6 ] [ Designated as safety issue: No ]
  • Percentage of participants who achieved Histologic response (Defined as CIN Grade less than [<] 2), determined by evaluation of tissue derived from surgical excision [ Time Frame: Month 6 ] [ Designated as safety issue: No ]
  • Percentage of participants with viral clearance based on Roche Linear assay results [ Time Frame: Months 3 and 6 ] [ Designated as safety issue: No ]
  • Percentage of participants with immunologic response to HPV antigens [ Time Frame: Day 1 (predose), Days 8, 15, and 29, Months 3 and 6 ] [ Designated as safety issue: No ]
  • Percentage of Participants with at least one Adverse Events (AEs) [ Time Frame: Up to Month 30 ] [ Designated as safety issue: No ]
  • Viral clearance by Roche HPV genomic testing [ Time Frame: at month 6 ] [ Designated as safety issue: No ]
  • Immunological response to HPV antigens [ Time Frame: after treatment and at intervals during follow-up ] [ Designated as safety issue: No ]
  • Safety and tolerability: adverse events, laboratory parameters [ Time Frame: Day 1 to Month 6, and at intervals during the 2 years of follow-up ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study of the Safety and Response Rate of 3 Subcutaneously Administered Doses of 5 X 10^7 PFU RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Grade 2 or 3 Associated With High Risk HPV Infection
This randomized, double-blind, placebo-controlled, parallel arm study will assess the safety and the efficacy of RO5217790 on histologic resolution in participants with high grade CIN associated with HR-HPV infection. Participants will be randomized to receive 3 subcutaneous injections of either placebo or RO5217790 on Days 1, 8, and 15. Study assessments will be made at Baseline, at Month 3 and 6, and every 6 months thereafter for an overall of 2.5 years.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Cervical Intraepithelial Neoplasia
  • Drug: Placebo
    Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
  • Drug: RO5217790
    RO5217790 will be administered at a dose of 5*10^7 pfu subcutaneously on Days 1, 8, and 15.
  • Placebo Comparator: Placebo
    Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
    Intervention: Drug: Placebo
  • Experimental: RO5217790
    RO5217790 will be administered at a dose of 5*10^7 plaque forming unit (pfu) subcutaneously on Days 1, 8, and 15.
    Intervention: Drug: RO5217790
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
206
September 2013
September 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Have a diagnosis within 2 months prior to the first dose of RO5217790 of CIN 2/3 confirmed by colposcopy-directed punch biopsy; patients must have at least 1 quadrant of residual CIN2/3 disease remaining after biopsy. Entry to the trial will be allowed based on the local assessment of this criterion; however, CIN 2/3 diagnosis will have to be confirmed by the central pathologist for the purposes of analyzing the study
  • Have satisfactory colposcopy, i.e. the entire acetowhite or disease area as well as the entire squamocolumnar junction visualized by colposcopy
  • Have detection at screening of a single or multiple HR-HPV infection by analysis of liquid based cytology (LBC) material on the Roche Linear Array assay consistent with any of the trial strata as specified in study protocol

Exclusion Criteria:

  • Have colposcopically visible CIN2/3 disease extending over more than 2 quadrants
  • Have any anatomical condition of the cervix, including that resulting from previous cervical surgery, congenital malformation or other condition, that would interfere with a complete evaluation of the transformation zone and surveillance of CIN. If an endocervical curettage (ECC) is performed, and the endocervical curettings reveal CIN, patients are eligible as long as the endocervical lesion is directly extending from the primary lesion and is colposcopically visible in its entirety
  • Have vulvar (VIN) or vaginal (VAIN) intraepithelial neoplasia
  • Have atypical endometrial or glandular cells or evidence of carcinoma on biopsy
  • Have a serious, concomitant disorder, including active systemic infection requiring treatment
  • Have a prior history of or current malignancy other than adequately treated skin cancer (squamous cell cancer or basal cell carcinoma), unless the history of skin cancer is at the site of study treatment administration
  • Have a proven or suspected immunosuppressive disorder or autoimmune disease
  • Have any significant cardiac, hepatic or renal disease
  • Have active viral infections including human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), cytomegalovirus (CMV), and Epstein barr virus (EBV) within 30 days of receiving study treatment. Mild viral infections such as Herpes Simplex Virus 1 (HSV-1) or common cold are not excluded
Female
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States,   Belgium,   Finland,   France,   Puerto Rico,   Spain
Germany,   Netherlands
 
NCT01022346
NV25025, 2008-006946-24
Not Provided
Not Provided
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
August 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP